US EditionPublished • loading... • Updated
Aphaia doses first subject in second Phase II obesity treatment trial
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Aphaia doses first subject in second Phase II obesity treatment trial
Aphaia Pharma has initiated the dosing of the first subject in a second Phase II trial focused on assessing its oral candidate for obesity.The post Aphaia doses first subject in second Phase II obesity treatment trial appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
